Press Releases

2024

May 2024 – Shift Pharmaceuticals Selected to Present at 2024 Peripheral Nerve Society Annual Meeting

Apr 2024 – Shift Pharmaceuticals Engages OGAdvisors for Business Development and Transactional Support

2023

Apr 2023 – Shift Pharmaceuticals Receives Phase I SBIR Funding for Treatment of CMT1A

2022

Nov 2022 – Shift Pharmaceuticals, CMTA Partner On ASO Treatment for CMT1A

May 2022 – Shift Pharmaceuticals receives funding from the National Institute of Neurological Disorders and Stroke

2020

May 2020 – FDA grants Orphan Drug status for Shift’s lead compound for SMA

Feb 2020 – Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A
treatment

2019

Dec 2019 – The Gwendolyn Strong Foundation and National Institute of Health fund Shift Pharmaceuticals

2018

Nov 2018 – Congressional Directed Medical Research Program (CDMRP) awards grant to Shift for the company’s lead compound for SMA